These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17214585)

  • 21. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
    Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
    Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
    Asano Y; Varga J
    Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
    Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
    Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of agents for the treatment of systemic sclerosis.
    Herrick AL
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1255-64. PubMed ID: 11772249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.
    Bhattacharyya S; Varga J
    Curr Rheumatol Rep; 2015 Jan; 17(1):474. PubMed ID: 25604573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.
    Bhattacharyya S; Varga J
    Immunol Lett; 2018 Mar; 195():9-17. PubMed ID: 28964818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
    Leask A
    Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
    McGaugh S; Kallis P; De Benedetto A; Thomas RM
    Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis.
    Liu Q; Lu J; Lin J; Tang Y; Pu W; Shi X; Jiang S; Liu J; Ma Y; Li Y; Xu J; Jin L; Wang J; Wu W
    Biomed Pharmacother; 2019 Feb; 110():546-553. PubMed ID: 30530290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma.
    Leask A
    Cell Signal; 2008 Aug; 20(8):1409-14. PubMed ID: 18296024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic sclerosis.
    Asano Y
    J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis.
    Paolini C; Agarbati S; Benfaremo D; Mozzicafreddo M; Svegliati S; Moroncini G
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.
    Liu X; Zhu S; Wang T; Hummers L; Wigley FM; Goldschmidt-Clermont PJ; Dong C
    PLoS Med; 2005 Dec; 2(12):e354. PubMed ID: 16250671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.
    Mostmans Y; Cutolo M; Giddelo C; Decuman S; Melsens K; Declercq H; Vandecasteele E; De Keyser F; Distler O; Gutermuth J; Smith V
    Autoimmun Rev; 2017 Aug; 16(8):774-786. PubMed ID: 28572048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.